Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation
NCT05017584Phase 4Withdrawn
- Sponsor
- Duke University
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of bupivacaine in pain (4 arms), sponsored by Duke University. Primary endpoint: Effective Dose 90. Planned start Jan 2023; status: withdrawn.
02
Drugs
bupivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05017584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017584.